<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"

 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://theoncologist.alphamedpress.org">
<title>THE ONCOLOGIST EXPRESS</title>
<link>http://theoncologist.alphamedpress.org</link>
<description>The Oncologist RSS feed -- Early Online Editions of Accepted Articles </description>
<eIssn>1549-490X</eIssn>
<publicationName>The Oncologist</publicationName>
<issn>1083-7159</issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0254v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0077v2?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0290v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0369v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0239v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0145v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0085v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0392v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0323v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0237v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0101v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2012-0335v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0349v1?rss=1" />
  <rdf:li rdf:resource="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0230v1?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.theoncologist.alphamedpress.org/icons/banner/title.gif" />
</channel>
<image rdf:about="http://hwmaint.theoncologist.alphamedpress.org/icons/banner/title.gif">
<title>The Oncologist</title>
<url>http://hwmaint.theoncologist.alphamedpress.org/icons/banner/title.gif</url>
<link>http://theoncologist.alphamedpress.org</link>
</image>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0254v1?rss=1">
<title><![CDATA[Adding Preoperative Radiotherapy Plus Cetuximab to Perioperative Chemotherapy for Resectable Esophageal Adenocarcinoma: A Single-Center Prospective Phase II Trial]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0254v1?rss=1</link>
<description><![CDATA[<sec><st>Background.</st><p>Local and systemic recurrence are important sources of treatment failure following surgical resection of esophageal adenocarcinoma. We hypothesized that adding preoperative cetuximab and radiotherapy (cetux-RT) to perioperative chemotherapy would increase treatment efficacy with acceptable toxicity.</p></sec><sec><st>Methods.</st><p>In this prospective phase II trial, patients were treated with three cycles of epirubicin, cisplatin, and capecitabine (ECX), followed by cetux-RT. After surgery with curative intent, patients received three more cycles of ECX. Primary endpoints were efficacy, determined by histopathological complete response (pCR) rate, and safety, which was assessed with resectability rate.</p></sec><sec><st>Results.</st><p>Of the 12 patients enrolled in this trial, six received at least one dose of cetux-RT. In five patients, cetux-RT was not started because of adverse events (AEs) related to preoperative chemotherapy; one patient had progressive disease. Addition of cetux-RT was well tolerated and did not interfere with the resectability rate (100%). However, the pCR rate was 0, and 50% of patients experienced serious adverse events (SAEs) postoperatively.</p></sec><sec><st>Conclusion.</st><p>With 12 patients enrolled, the lack of initial signs of efficacy and a high incidence of postoperative SAEs prompted us to end this study prematurely. Perioperative ECX was associated with considerable toxicity, and further treatment intensification is problematic.</p></sec>]]></description>
<creator><![CDATA[Ubink, I., van der Sluis, P., Schipper, M., Reerink, O., Voest, E., Borel-Rinkes, I., Wijrdeman, H., Vleggaar, F., Agterof, M., Overkleeft, E., Siersema, P., van Hillegersberg, R., Lolkema, M.]]></creator>
<date>2013-12-12T13:23:59-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0254</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0254</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Adding Preoperative Radiotherapy Plus Cetuximab to Perioperative Chemotherapy for Resectable Esophageal Adenocarcinoma: A Single-Center Prospective Phase II Trial]]></title>
<publicationDate>2013-12-12</publicationDate>
<section>CLINICAL TRIAL RESULTS</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0077v2?rss=1">
<title><![CDATA[U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0077v2?rss=1</link>
<description><![CDATA[<p>The authors report relevant clinical information regarding the U.S. Food and Drug Administration approval of a new drug, omacetaxine mepesuccinate (Synribo), for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors. Omacetaxine mepesuccinate has shown activity and a favorable benefit to risk profile for the studied population. Further evidence of response durability to verify clinical benefit is pending.</p>]]></description>
<creator><![CDATA[Alvandi, F., Kwitkowski, V. E., Ko, C.-W., Rothmann, M. D., Ricci, S., Saber, H., Ghosh, D., Brown, J., Pfeiler, E., Chikhale, E., Grillo, J., Bullock, J., Kane, R., Kaminskas, E., Farrell, A. T., Pazdur, R.]]></creator>
<date>2013-12-11T14:14:21-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0077</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0077</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia]]></title>
<publicationDate>2013-12-11</publicationDate>
<section>REGULATORY ISSUES: FDA</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0290v1?rss=1">
<title><![CDATA[Barriers and Challenges to Global Clinical Cancer Research]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0290v1?rss=1</link>
<description><![CDATA[<p>Using data from the American Society of Clinical Oncology International Affairs Committee&rsquo;s Web survey of selected oncologists with research experience from 25 countries, the authors explored the characteristics of and barriers to global clinical cancer research. They concluded that lack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research.</p>]]></description>
<creator><![CDATA[Seruga, B., Sadikov, A., Cazap, E. L., Delgado, L. B., Digumarti, R., Leighl, N. B., Meshref, M. M., Minami, H., Robinson, E., Yamaguchi, N. H., Pyle, D., Cufer, T.]]></creator>
<date>2013-12-09T14:41:58-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0290</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0290</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Barriers and Challenges to Global Clinical Cancer Research]]></title>
<publicationDate>2013-12-09</publicationDate>
<section>GLOBAL HEALTH AND CANCER</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0369v1?rss=1">
<title><![CDATA[Zollinger-Ellison Syndrome: Classical Considerations and Current Controversies]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0369v1?rss=1</link>
<description><![CDATA[<p>Surgery plays a key role in the management of Zollinger-Ellison syndrome; however, extent of resection, timing of intervention, performance of prophylactic adjunctive procedures, and reoperation for recurrent disease are topics of controversy. Historical considerations as well as evidence-based recommendations are summarized in this review.</p>]]></description>
<creator><![CDATA[Epelboym, I., Mazeh, H.]]></creator>
<date>2013-12-06T13:06:29-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0369</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0369</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Zollinger-Ellison Syndrome: Classical Considerations and Current Controversies]]></title>
<publicationDate>2013-12-06</publicationDate>
<section>ENDOCRINOLOGY</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0239v1?rss=1">
<title><![CDATA[New Oral Anticoagulants and the Cancer Patient]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0239v1?rss=1</link>
<description><![CDATA[<p>New oral anticoagulants are now available that offer increased options for anticoagulation beyond the traditional vitamin K antagonists. In this report, the basic pharmacology, current clinical indications, and approach to the use of new oral anticoagulants in the cancer patient have been reviewed.</p>]]></description>
<creator><![CDATA[Short, N. J., Connors, J. M.]]></creator>
<date>2013-12-06T13:06:29-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0239</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0239</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[New Oral Anticoagulants and the Cancer Patient]]></title>
<publicationDate>2013-12-06</publicationDate>
<section>NEW DRUG DEVELOPMENT AND CLINICAL PHARMACOLOGY</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0145v1?rss=1">
<title><![CDATA[Prediction of Post-Chemotherapy Ovarian Function Using Markers of Ovarian Reserve]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0145v1?rss=1</link>
<description><![CDATA[<p>Chemotherapy results in transient or permanent ovarian failure in the majority of women. Prechemotherapy assessment of serum anti-M&uuml;llerian hormone may be useful for predicting postchemotherapy ovarian function. This finding has implications for decision making about adjuvant endocrine therapy in premenopausal women treated with chemotherapy.</p>]]></description>
<creator><![CDATA[Henry, N. L., Xia, R., Schott, A. F., McConnell, D., Banerjee, M., Hayes, D. F.]]></creator>
<date>2013-12-06T13:06:28-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0145</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0145</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Prediction of Post-Chemotherapy Ovarian Function Using Markers of Ovarian Reserve]]></title>
<publicationDate>2013-12-06</publicationDate>
<section>GYNECOLOGIC ONCOLOGY</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0085v1?rss=1">
<title><![CDATA[Reducing Lung Cancer and Other Tobacco-Related Cancers in Europe: Smoking Cessation Is the Key]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0085v1?rss=1</link>
<description><![CDATA[]]></description>
<creator><![CDATA[Clancy, L.]]></creator>
<date>2013-12-06T13:06:28-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0085</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0085</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Reducing Lung Cancer and Other Tobacco-Related Cancers in Europe: Smoking Cessation Is the Key]]></title>
<publicationDate>2013-12-06</publicationDate>
<section>EUROPEAN PERSPECTIVES</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0392v1?rss=1">
<title><![CDATA[A New Model for Reimbursing Genome-Based Cancer Care]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0392v1?rss=1</link>
<description><![CDATA[]]></description>
<creator><![CDATA[Ramsey, S. D., Sullivan, S. D.]]></creator>
<date>2013-12-05T10:54:28-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0392</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0392</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[A New Model for Reimbursing Genome-Based Cancer Care]]></title>
<publicationDate>2013-12-05</publicationDate>
<section>COMMENTARY</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0323v1?rss=1">
<title><![CDATA[Local and Regional Staging of Invasive Breast Cancer With Sonography: 25 Years of Practice at MD Anderson Cancer Center]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0323v1?rss=1</link>
<description><![CDATA[<p>It has been observed that sonography is rarely used by many institutions in the local or regional staging of breast cancer. Findings suggest, however, that sonography has shown sufficient accuracy in clinical practice to stage most invasive breast cancers.</p>]]></description>
<creator><![CDATA[Fornage, B. D.]]></creator>
<date>2013-12-05T10:54:28-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0323</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0323</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Local and Regional Staging of Invasive Breast Cancer With Sonography: 25 Years of Practice at MD Anderson Cancer Center]]></title>
<publicationDate>2013-12-05</publicationDate>
<section>BREAST CANCER</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0237v1?rss=1">
<title><![CDATA[Hypothyroidism After a Cancer Diagnosis: Etiology, Diagnosis, Complications, and Management]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0237v1?rss=1</link>
<description><![CDATA[<p>This paper highlights the role that hypothyroidism can play in the diagnosis, treatment, and recovery of cancer. Timely diagnosis and treatment is pertinent to minimize the complications of hypothyroidism, to optimize cancer therapy, and to minimize recurrence. The authors discuss newer therapies associated with hypothyroidism and the negative impact that hypothyroidism can have in patients with a malignancy.</p>]]></description>
<creator><![CDATA[Carter, Y., Sippel, R. S., Chen, H.]]></creator>
<date>2013-12-05T10:54:28-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0237</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0237</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Hypothyroidism After a Cancer Diagnosis: Etiology, Diagnosis, Complications, and Management]]></title>
<publicationDate>2013-12-05</publicationDate>
<section>ENDOCRINOLOGY</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0101v1?rss=1">
<title><![CDATA[Low Incidence of Pseudoprogression by Imaging in Newly Diagnosed Glioblastoma Patients Treated With Cediranib in Combination With Chemoradiation]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0101v1?rss=1</link>
<description><![CDATA[<p>This study sought to determine whether the addition of a vascular endothelial growth factor signaling inhibitor (cediranib) to conventional chemoradiation had an impact on the frequency of pseudoprogression. The results show that administration of a VEGF inhibitor during and after chemoradiation modifies the expression of pseudoprogression by imaging.</p>]]></description>
<creator><![CDATA[Pinho, M. C., Polaskova, P., Kalpathy-Cramer, J., Jennings, D., Emblem, K. E., Jain, R. K., Rosen, B. R., Wen, P. Y., Sorensen, A. G., Batchelor, T. T., Gerstner, E. R.]]></creator>
<date>2013-12-05T10:54:28-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0101</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0101</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Low Incidence of Pseudoprogression by Imaging in Newly Diagnosed Glioblastoma Patients Treated With Cediranib in Combination With Chemoradiation]]></title>
<publicationDate>2013-12-05</publicationDate>
<section>NEURO-ONCOLOGY</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2012-0335v1?rss=1">
<title><![CDATA[Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2012-0335v1?rss=1</link>
<description><![CDATA[<p>An international multicenter retrospective study of sunitinib-treated metastatic renal cell carcinoma patients was performed to determine the association between outcome and the pretreatment status of smoking, body mass index, hypertension, diabetes, and other known prognostic factors. The results showed that active smoking may negatively affect the progression-free and overall survival of these patients.</p>]]></description>
<creator><![CDATA[Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R., Carducci, M. A.]]></creator>
<date>2013-12-05T10:54:27-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2012-0335</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2012-0335</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib]]></title>
<publicationDate>2013-12-05</publicationDate>
<section>GENITOURINARY CANCER: RENAL, BLADDER, AND TESTICULAR</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0349v1?rss=1">
<title><![CDATA[On Being a Doll]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0349v1?rss=1</link>
<description><![CDATA[]]></description>
<creator><![CDATA[Montero, A. J.]]></creator>
<date>2013-12-04T06:52:15-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0349</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0349</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[On Being a Doll]]></title>
<publicationDate>2013-12-04</publicationDate>
<section>REFLECTIONS</section>
</item>
<item rdf:about="http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0230v1?rss=1">
<title><![CDATA[Reducing Tobacco-Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop]]></title>
<link>http://theoncologist.alphamedpress.org/cgi/content/short/theoncologist.2013-0230v1?rss=1</link>
<description><![CDATA[<p>It has been observed that tobacco use remains a serious and persistent national problem. This report summarizes a public workshop convened by the Institute of Medicine's National Cancer Policy Forum that examined current issues in tobacco control, tobacco cessation, and implications for cancer patients.</p>]]></description>
<creator><![CDATA[Balogh, E. P., Dresler, C., Fleury, M. E., Gritz, E. R., Kean, T. J., Myers, M. L., Nass, S. J., Nevidjon, B., Toll, B. A., Warren, G. W., Herbst, R. S.]]></creator>
<date>2013-12-04T06:52:15-08:00</date>
<identifier>info:doi/10.1634/theoncologist.2013-0230</identifier>
<identifier>hwp:master-id:theoncologist;theoncologist.2013-0230</identifier>
<publisher>AlphaMed Press</publisher>
<title><![CDATA[Reducing Tobacco-Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop]]></title>
<publicationDate>2013-12-04</publicationDate>
<section>CANCER PREVENTION</section>
</item>
</rdf:RDF>